SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development

Core Insights - SureNano Science Ltd. has acquired GlucaPharm Inc., enhancing its position in the pharmaceutical market focused on obesity and metabolic diseases with the development of GEP44, a next-generation glucagon-like peptide (GLP) [2][8] Company Overview - GlucaPharm is developing GEP44, a patented peptide that aims to provide weight reduction and blood glucose normalization with fewer side effects compared to existing GLP-1 drugs like Ozempic® and Wegovy® [5][10] - SureNano Science Ltd. is transitioning from an enabling-technology company to a pharmaceutical value creator, targeting the rapidly growing global drug market [2][8] Acquisition Details - The acquisition was structured as a share exchange, with SureNano issuing 8,100,999 common shares and warrants for 5,000,000 common shares to GlucaPharm shareholders [3] - The shares issued will have a hold period until certain conditions are met, including approval from the Canadian Securities Exchange [3] Leadership and Expertise - Dr. Nihar R. Pandey has been appointed as Director and Chief Scientific Officer, bringing over 25 years of experience in drug discovery and development [4] Product Development - GEP44 is expected to advance through an IND-enabling FDA study and Phase I Clinical Trial in Australia, with key milestones anticipated in the next six to nine months [7][9] - The global GLP market is currently dominated by injectable therapies, and GlucaPharm aims to develop non-injectable delivery methods to enhance patient adoption [6][9] Market Potential - The GLP-1 metabolic market is projected to be multi-hundred-billion dollars, and SureNano aims to position itself as a significant player alongside large pharmaceutical companies [9]